Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Equity (2020 - 2025)

Historic Return on Equity for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to 15.14%.

  • Insight Molecular Diagnostics' Return on Equity rose 168300.0% to 15.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.14%, marking a year-over-year increase of 168300.0%. This contributed to the annual value of 14.9% for FY2024, which is 147900.0% down from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Return on Equity stood at 15.14% for Q3 2025, which was up 168300.0% from 11.27% recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Return on Equity peaked at 56.98% during Q1 2025, and registered a low of 11.27% during Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' median Return on Equity value was 0.57% (recorded in 2024), while the average stood at 6.68%.
  • The largest annual percentage gain for Insight Molecular Diagnostics' Return on Equity in the last 5 years was 575500bps (2025), contrasted with its biggest fall of -104700bps (2025).
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Return on Equity stood at 0.82% in 2021, then fell by -27bps to 1.04% in 2022, then skyrocketed by 90bps to 0.1% in 2023, then skyrocketed by 47227bps to 47.52% in 2024, then plummeted by -68bps to 15.14% in 2025.
  • Its Return on Equity stands at 15.14% for Q3 2025, versus 11.27% for Q2 2025 and 56.98% for Q1 2025.